Clarinex (Desloratadine) Interactions
Clarinex (Desloratadine) Interactions
Elevations in desloratadine serum concentrations and its metabolite (3-hydroxydesloratadine) are observed when desloratadine is co-administered with erythromycin, ketoconazole, azithromycin, fluoxetine or cimetidine.[7530] [8000] Erythromycin increased desloratadine peak concentrations by 24% and increased AUC by 14%. Ketoconazole increased desloratadine peak concentrations by 45% and increased AUC by 39%. Changes with azithromycin, fluoxetine and cimetidine were less significant (roughly 15% increase in Cmax) than with erythromycin or ketoconazole. Although there appears to be some inhibition of cytochrome P450 mediated metabolism of desloratadine by erythromycin or ketoconazole, there are no significant changes in ventricular rate or function. These interactions are not considered clinically significant. Clinically meaningful changes in the QTc intervals have not occurred in patients receiving recommended doses of desloratadine.[7530]
Although desloratadine is considered a ‘non-sedating’ antihistamine, rare CNS effects such as dizziness and sedation have been reported.[7530] For this reason, it would be prudent to monitor for drowsiness or dizziness when used concurrently with other CNS depressants such as barbiturates, benzodiazepines, opiate agonists, antipsychotics, tricyclic antidepressants, ethanol, other H1-blockers, and anxiolytics, sedatives, and hypnotics.
[ Last revised: 5/5/2005 8:57:00 AM ]
References
7530. Clarinex® (desloratadine) package insert. Kenilworth, NJ: Schering Corporation; 2002 Feb.
8000. Clarinex-D® 24-Hour Extended Release Tablets (desloratadine; pseudoephedrine) package insert. Kenilworth, NJ: Schering Corporation; 2005 March.
Related entries
Syndicate
|
